Mounjaro vs. Rybelsus

See how Mounjaro and Rybelsus compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Mounjaro is a once-weekly injection that acts on two hormone pathways, while Rybelsus is a daily pill that acts on one.

  • Both carry the same boxed warning for thyroid tumors and share overlapping side effects like nausea and diarrhea.

  • Rybelsus also reduces cardiovascular risk in adults with type 2 diabetes and existing heart disease, an indication Mounjaro does not have.

Mounjaro vs. Rybelsus Drug Summary

Mounjaro

Mounjaro (tirzepatide) is a GIP/GLP-1 receptor agonist injected once a week to manage blood sugar in adults and children 10 and older with type 2 diabetes. The dose starts low and increases roughly every four weeks up to a maintenance dose of 15 mg. Many people also use it off-label for weight loss.

Rybelsus

Rybelsus (semaglutide) is a GLP-1 receptor agonist taken as a daily pill to manage blood sugar in adults with type 2 diabetes. It also lowers cardiovascular risk in patients with existing heart disease, with the dose increasing from 3 mg to 14 mg over about two months. Some people use it off-label for weight loss.

Mounjaro vs. Rybelsus Side Effects

Mounjaro

Most common
nausea (12-18%)
diarrhea (12-17%)
decreased appetite (8-11%)
vomiting (5-9%)

Rybelsus

Most common
nausea (up to 20%)
diarrhea (up to 10%)
decreased appetite (up to 9%)
vomiting (up to 8%)

Mounjaro vs. Rybelsus Dosage

Mounjaro

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 2.5 mg once weekly Weeks 1-4
Maximum dose 15 mg once weekly Week 21 onward
Dose changes 5 increases Every 4 weeks

Rybelsus

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 3 mg once daily Days 1-30
Maximum dose 14 mg once daily Day 61 onward
Dose changes 2 increases Every 30 days

Mounjaro vs. Rybelsus Indications

Mounjaro

Mounjaro is FDA-approved to improve blood sugar control in adults and children 10 and older with type 2 diabetes. It is not approved for type 1 diabetes or as a standalone weight-loss drug, though many prescribers use it off-label for that purpose.

  • Blood sugar control in adults with type 2 diabetes

  • Blood sugar control in pediatric patients 10 and older

  • Off-label: weight loss in people without diabetes

  • Not approved for type 1 diabetes

Rybelsus

Rybelsus is FDA-approved to improve blood sugar control in adults with type 2 diabetes and to reduce cardiovascular risk in those with existing heart disease. It is not approved for type 1 diabetes or chronic weight management, though it is sometimes used off-label for weight loss.

  • Blood sugar control in adults with type 2 diabetes

  • Reduces cardiovascular risk with existing heart disease

  • Off-label: weight loss in people without diabetes

  • Not approved for type 1 diabetes or weight management

Mounjaro vs. Rybelsus Pros and Cons

Mounjaro

Mounjaro's dual-hormone mechanism is linked to larger average reductions in blood sugar and weight than single-pathway GLP-1 drugs, but it requires a weekly injection rather than a pill. Insurance coverage varies and often hinges on a documented type 2 diabetes diagnosis.

Pros

  • Dual GIP/GLP-1 action often produces larger blood sugar and weight reductions

  • Approved for children 10 and older with type 2 diabetes

  • Weekly injection means fewer doses to remember than a daily pill

  • Flexible dose range up to 15 mg for patients needing more control

Cons

  • Requires a weekly self-injection rather than a pill

  • Not approved for cardiovascular risk reduction

  • Slightly higher reported vomiting rate in trials

  • No pediatric data below age 10

Rybelsus

Rybelsus offers the convenience of an oral tablet, which appeals to people who prefer to avoid injections, but it requires strict fasting and water rules each morning to absorb properly. It is the only GLP-1 drug also approved to reduce cardiovascular risk in adults with type 2 diabetes and heart disease.

Pros

  • Oral tablet avoids the need for injections

  • Only oral GLP-1 approved to reduce cardiovascular risk

  • Longer track record, approved since 2019

  • Simpler three-step dose titration schedule

Cons

  • Must be taken on an empty stomach with a small sip of water

  • Cannot eat or drink for 30 minutes after taking it

  • Not approved for pediatric use or chronic weight management

  • Highest reported nausea rate between the two drugs

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.